Miscellaneous Respiratory Disorders

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

By December 07, 2018

The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.

Montelukast With or Without Intranasal Steroids Evaluated for Pediatric OSA

By December 05, 2018

A team of authors performed a systematic review of studies examining anti-inflammatory treatments for pediatric OSA through June 28, 2018 using PubMed/MEDLINE and 4 other databases.

Climate Change Ups Heat Deaths, Especially Among Elderly

November 30, 2018

Last year, 157 million at-risk people were exposed to heat waves worldwide; 18 million more than in 2016.

Vitamin D Levels Linked to Cardiorespiratory Fitness

November 27, 2018

The researchers found that participants in the highest quartile of vitamin D levels had significantly higher cardiorespiratory fitness than participants in the lowest quartile.

Sildenafil does not improve QoL for idiopathic pulmonary fibrosis patients treated with nintedanib

November 02, 2018

In patients with idiopathic pulmonary fibrosis (IPF) and a low diffusion capacity for carbon dioxide (DLCO), the addition of sildenafil to a treatment regimen of nintedanib did not improve quality of life scores after 12 weeks compared to treatment with nintedanib and a placebo.

Severe Acute Respiratory Distress Syndrome Following HCTZ Administration

By October 31, 2018

"One of the most commonly prescribed antihypertensives, HCTZ is associated with rare cases of pulmonary edema, which typically develop within minutes to hours of the initial dose of the medication," the study authors stated.

Triple Combo Regimens May Address Cause of Cystic Fibrosis

October 19, 2018

The researchers observed significant improvement in the processing and trafficking of the Phe508del CFTR protein with VX-659-tezacaftor-ivacaftor, as well as improved chloride transport in vitro.

Dupilumab Studies Show Benefit in Chronic Rhinosinusitis With Nasal Polyps

By October 16, 2018

In both studies, at 24 weeks, patients treated with dupilumab plus corticosteroid nasal spray experienced a 51% and 57% improvement in nasal congestion/obstruction severity vs 15% and 19% improvement with nasal spray alone.

High Flow Nasal Cannula Oxygen Therapy May Benefit Elderly Patients in ICU

October 12, 2018

After high flow nasal cannula oxygen therapy, 15% of patients had to be intubated and mechanically ventilated, but the majority stepped down to regular oxygen therapy.

Pirfenidone Effective for Improving Pulmonary Fibrosis Symptoms

October 12, 2018

When treated with pirfenidone, patients with idiopathic pulmonary fibrosis experienced significant improvements in 6-minute walking distance and University of California San Diego Shortness of Breath Questionnaire scores.

Novel Inhaled Treatment for Cystic Fibrosis Granted Orphan Drug Designation

By October 11, 2018

SNSP113 is intended to improve lung function in CF patients by targeting key drivers of pulmonary decline such as infection, airway congestion and inflammation.

Red Tide May Be Cause of Florida Beachgoers' Breathing Problems

October 04, 2018

People who develop symptoms should leave the beach and find someplace cool.

Nuzyra Approved for CABP, Acute Skin/Skin Structure Infections

By October 03, 2018

The approval was based on Phase 3 data from 2 studies in ABSSSI, where treatment with Nuzyra was compared with linezolid, and 1 study in CABP comparing Nuzyra with moxifloxacin. Across all 3 trials, Nuzyra was found to be effective and generally safe and well-tolerated.

Telemedicine RTI Visits Shorter When Antibiotic Prescribed

October 02, 2018

"Because telemedicine encounters are short and physicians are often reimbursed by encounter volume, antibiotic stewardship efforts that lengthen visits even slightly may be challenging to implement," the authors write.

Arikayce Approved to Treat <i>Mycobacterium Avium</i> Complex Lung Disease

By October 01, 2018

Arikayce is intended for oral inhalation use and is administered via the Lamira Nebulizer System only.

Nintedanib Plus Sildenafil No Better Than Nintedanib in IPF

September 28, 2018

The researchers found that there was no significant difference between the nintedanib-plus-sildenafil group and the nintedanib group in terms of the adjusted mean change from baseline in the SGRQ total score at week 12 (−1.28 and −0.77 points, respectively; P=.72).

Low Vitamin D Levels Tied to Interstitial Lung Disease

September 21, 2018

There was an association between 25(OH)D deficiency and increased prevalence of interstitial lung abnormalities 10 years later.

Factors Predictive of Escalated Care in Infant Bronchiolitis ID'd

September 18, 2018

Multivariable predictors included oxygen saturation <90%, nasal flaring and/or grunting, apnea, retractions, age ≤2 months, dehydration, and poor feeding (odds ratios, 8.9, 3.8, 3.0, 3.0, 2.1, 2.1, and 1.9, respectively).

Ofev Slows Idiopathic Pulmonary Fibrosis Progression Long-Term

By September 17, 2018

The primary objective was to characterize the long-term safety and tolerability of Ofev in patients with IPF; efficacy endpoints included annual rate of decline in forced vital capacity (FVC) calculated over 192 weeks.

FDA Fast-Tracks Pamrevlumab for Idiopathic Pulmonary Fibrosis

By September 12, 2018

The FDA's designation was based on data from a Phase 2 placebo-controlled trial that demonstrated pamrevlumab could potentially address an unmet medical need for this condition.

Positive Results for Zerbaxa in Phase 3 Study of Ventilated HABP, VABP Patients

By September 11, 2018

The full findings from the study will be presented at a future scientific conference; Merck plans to include the data in a supplemental New Drug Application for Zerbaxa which will be submitted to the Food and Drug Administration.

FDA Warns of Dangers of Liquid Nitrogen in Food, Drinks

September 04, 2018

Liquid nitrogen isn't toxic, but its extremely low temperature can cause severe damage to skin and internal organs if mishandled or consumed, the FDA said in a news release.

FDA: Hundreds of Human, Pet Homeopathy Products Recalled

August 29, 2018

Those at highest risk from the recalled products include infants, children, pregnant women, and people with weakened immune systems, the FDA said.

Glucocorticoid Therapy Examined in Pediatric Patients With Croup

By August 23, 2018

Forty-three randomized controlled trials (N=4565) were included in the analysis, 5 more than in the previous review.

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

August 22, 2018

It predicts between 470 and 1,400 premature deaths a year by 2030 because of increased levels of microscopic airborne particulates, which are linked with heart and lung disease and chronic problems like asthma and bronchitis, The Times reported.

Keytruda With Pemetrexed + Platinum Chemotherapy OK'd for Nonsquamous NSCLC

By August 21, 2018

The median OS was not reached at the time of the data cut-off in the pembrolizumab plus chemotherapy arm and was 11.3 months for those in the chemotherapy arm.

Opdivo Approved to Treat Metastatic Small Cell Lung Cancer

By August 20, 2018

Data showed that 12% responded to treatment based on assessment by a Blinded Independent Central Review, regardless of PD-L1 expression; 11% had a partial response, and 1 patient had a complete response (0.9%).

Treatment for Bronchiolitis Obliterans Gains Orphan Drug Status

By August 15, 2018

Bronchiolitis obliterans is the leading cause of morbidity and mortality in the pulmonary transplant population with ≥50% of patients who receive a lung transplant developing the condition within 5 years.

Omadacycline Gets FDA Committee Nod for Skin Infections, Pneumonia

By August 09, 2018

The Committee's recommendation was based on data from the omadacycline global development program that included nearly 2000 adults in three Phase 3 studies.

FDA Panel Votes on Therapy for Nontuberculous Mycobacterial Lung Disease

By August 09, 2018

The recommendation was supported by materials developed from the ALIS New Drug Application (NDA), which included data from the CONVERT study.